Validation of the 21-Gene Test as a Predictor of Clinical Response to Neoadjuvant Hormonal Therapy for ER+, HER2-negative Breast Cancer: The TransNEOS Study
Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-018-4964-y
Full Text
Open PDFAbstract
Available in full text
Date
September 21, 2018
Authors
Publisher
Springer Science and Business Media LLC